Rapid growth from $1.64 billion in 2017 to $6.07 billion in 2024 is expected in the global orphan and rare dermatology premium products market, according to business intelligence provider, GBI Research. Read more


Almirall has acquired the rights to Veltin and Altabax, from Stiefel, a GSK company, in exchange for distribution rights to Toctino and an undisclosed cash payment Read more


Valeant Pharmaceuticals International has completed the sale to Galderma of all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4 billion in cash, pursuant to the previously announced agreement with Nestle Read more